MBRX News and Press, Moleculin Biotech Inc. From 02/05/21

VANCOUVER, British Columbia, Feb. 05, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “ Company ” or “ WPD ”) a clinical-stage pharmaceutical company, is pleased to announce that that Moleculin Biotech Inc. (NASDAQ:MBRX) ...

Gainers: Tyme Technologies (TYME) +93%.Sino-Global Shipping America (SINO) +81%.Lizhi (LIZI) +70%.Cassava Sciences (SAVA) +48%.GW Pharmaceuticals (GWPH) +46%.CPS Technologies (CPSH) +41%.10X Capital Venture Acquisition (VCVC) +38%.Naked Brand (NAKD) +37%.SuperCom (SPCB) +34%.Am...

Gainers: Tyme Technologies (TYME) +110%, GW Pharmaceuticals (GWPH) +47%, Zynerba Pharmaceuticals (ZYNE) +39%, SELLAS Life Sciences (SLS) +38%, InMed Pharmaceuticals (INM) +15%.Losers: Vaxart (VXRT) -51%, Moleculin Biotech (MBRX) -26%...

Moleculin Announces Pricing Of $67.8 Million Underwritten Public Offering PR Newswire HOUSTON , Feb. 3, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfoli...

Moleculin Biotech (MBRX) announces that it intends to offer and sell shares in an underwritten public offering.The company plans to use the net proceeds of the offering to fund its planned clinical trials and preclinical programs among other things.As part of this offering, Moleculin intends ...

Gainers: Cassava Sciences (SAVA) +126%.Ocugen (OCGN) +75%.American Resources (AREC) +51%.Lizhi (LIZI) +46%.Aeterna Zentaris (AEZS) +35%.Moleculin Biotech (MBRX) +35%.Holicity (HOL) +35%.Prothena (PRTA) +32%.TETRA Technologies (TTI) +32%.Artelo Biosciences (ARTL) +29%.Losers: Ga...

Clinical stage pharma company Moleculin Biotech (MBRX) shares skyrocketed in premarket trading after it announced that a preclinical study in animals showed a potentially significant therapeutic benefit of its Annamycin treatment against metastatic osteosarcoma.Scans showed that ani...

Artelo Biosciences (ARTL) +78%.Moleculin Biotech (MBRX) +49% on announcing 100% survival achieved in Osteosarcoma Lung Metastases Animal Model.DURECT (DRRX) +42% after FDA approval for Posimir.Holicity (HOLUU) +38% on plan to take rocket maker Astra public.Tiziana Life Sciences...

Moleculin Announces 100% Survival Achieved in Osteosarcoma Lung Metastases Animal Model Annamycin shown to reach "sanctuary sites" of cancer PR Newswire HOUSTON , Feb. 2, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company),...

Moleculin Signs Agreement with Catalyst Clinical Research to Begin Sarcoma Trial Annamycin being used to target soft tissue sarcoma lung metastases PR Newswire HOUSTON , Feb. 1, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or t...